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Patients with chronic kidney disease (CKD) represent an
important segment of the population (7–10%) and, mostly
because of the high risk of cardiovascular complications
associated with renal insufficiency, detection and treatment
of CKD is now a public health priority. Traditional risk factors
can incite renal dysfunction and cardiovascular damage as
well. As renal function deteriorates, non-traditional risk
factors play an increasing role both in glomerular filtration
rate (GFR) loss and cardiovascular damage. Secondary
analyses of controlled clinical trials suggest that
inflammation may be a modifiable risk factor both for cardiac
ischemia and renal disease progression in patients with or at
risk of coronary heart disease. Homocysteine predicts renal
function loss in the general population and cardiovascular
events in end-stage renal disease (ESRD), but evidence that
this sulfur amino acid is directly implicated in the progression
of renal disease and in the high cardiovascular mortality of
uremic patients is still lacking. High sympathetic activity and
raised plasma concentration of asymmetric dimethylarginine
(ADMA) have been associated to reduced GFR in patients
with CKD and to cardiovascular complications in those with
ESRD but again we still lack clinical trials targeting these risk
factors. Presently, the clinical management of CKD patients
remains largely unsatisfactory because only a minority of
these attain the treatment goals recommended by current
guidelines. Thus, in addition to research into new and
established risk factors, it is important that nephrologists
make the best use of knowledge already available to
optimize the follow-up of these patients.
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Nephrology has long been considered a niche specialty. Renal
physicians are perceived as experts in relatively unusual
immunologic diseases (such as lupus) and rare or orphan
diseases. Even end-stage renal disease (ESRD), an often-used
measure for quantifying the burden of chronic renal disease,
is a rare condition affecting only one individual/1000 in the
general population. In contrast, the heart failure syndrome
alone has a prevalence of about 20/1000 in the general
population. During the last 10 years or so, however,
considerable evidence has accrued that mild-to-moderate
degrees of renal insufficiency are much more frequent at the
population level. Even more important, modest degrees of
renal dysfunction imply a high cardiovascular risk. In this
review, I will summarize the epidemiologic knowledge about
the frequency of renal insufficiency both at the population
level and in specific disease states, on cardiovascular risk in
patients with varying degrees of renal insufficiency, on risk
factors for renal disease progression and cardiovascular
complications, and I will conclude with a brief overview on
preventive strategies. Rather than providing an exhaustive
assessment of risk factors peculiar to chronic kidney disease
(CKD), like anemia, hyperphosphatemia, and vascular
calcification, that are well covered in recent systematic and
narrative reviews (see below), the principal scope of this
appraisal is that of emphasizing the role of traditional risk
factors and of updating knowledge on selected emerging risk
factors.
RENAL INSUFFICIENCY: AN EPIDEMIOLOGIC OVERVIEW
Since much of the issues discussed in this review pertain to
the risk of disease (be it renal or cardiovascular), it is useful
to review the concept of ‘risk factor’ as formulated by Kannel
almost 30 years ago.1 Risk factors are markers that are
statistically, but not necessarily causally, related to subsequent
morbid events. The identification of causal risk factors, for
example, smoking, has critical importance because it can
allow interventions aimed directly at reducing or eliminating
the deleterious factor in question. Non-causal risk factors
(disease markers, e.g., serum creatinine) are useful in
monitoring the evolution of a given disease and for
prognostic purposes. Risk factors also include structural
surrogates of impending cardiovascular events, for example,
atherosclerosis as detected by echo-Doppler techniques or
left-ventricular hypertrophy (LVH) detected by electrocar-
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diogram or cardiac echography. These structural surrogates
of subsequent cardiovascular events reflect the pathophysio-
logic processes that lead to heart failure, myocardial
infarction, etc. The dimension of time is fundamental for
correct interpretation of the association between a purported
risk factor and a given event. Indeed, cross-sectional studies
(surveys) are generally far more prone to bias than are
prospective (cohort) studies. As the link between risk factors
and clinical outcomes varies in different populations and
disease states, validation of prognostic factors demands that
they be specifically tested in the particular population in
which they will be applied. This concept is particularly true in
ESRD, where ‘reverse causality’ is pervasive.
Knowledge of the frequency of renal insufficiency at the
community level remains limited. In fact, the only solid
databases providing such information in samples representa-
tive of the American population are those of the III and IV
National Health and Nutrition Examinations Surveys
(NHANES). In these surveys, a moderate degree of renal
impairment (glomerular filtration rate (GFR) 15–59 ml/min/
1.73 m2, as estimated by the Modification of Diet in Renal
Disease (MDRD) formula) had a 4.2 and 3.7% prevalence,
respectively.2 Diabetes mellitus and age were strongly
associated with renal insufficiency because the risk was 2.8
(NHANES II) and 4.9 (NHANES III) times higher in diabetic
than in non-diabetic subjects and 10 times higher in subjects
older than 60 years than in younger subjects.3 This strong age
dependence of renal insufficiency also emerged in an analysis
based on a community-derived sample from the Framingham
Offspring study, a survey that identified older age treatment
for hypertension and diabetes as important correlates of high
serum creatinine levels.4 These observations were subse-
quently confirmed in longitudinal analyses of the same
database.5 Smoking, low high-density lipoprotein cholesterol,
and mild renal insufficiency at baseline represented addi-
tional independent predictors of further renal function
deterioration. Comparable information from outside the
USA is scarce. In the AusDiab study, the prevalence of
moderate renal failure (GFRo60, 430 ml/min/m2) as
assessed by the Cockcroft–Gault method was even more
alarming, reaching 11%.6 In the framework of an exemplary
initiative aimed at generating epidemiological knowledge on
renal dysfunction at population level in Groningen, the
PREVEND study,7 the incidence rate of moderate renal
insufficiency was 4.2% in 4 years.8 In the Framingham
Offspring study, the incidence of moderate CKD was 9.4% in
18.5 years5 and in the Atherosclerosis Risk in Communities
study it was 7% in 9 years.9 Thus, both in the USA and in
Europe CKD is more frequent than previously thought.
The diabetic and hypertensive populations, elderly
individuals, and those who chronically use anti-inflamma-
tory agents are prototypical high-risk populations for
renal insufficiency.10 In the NHANES I and II cohorts, mild
renal insufficiency developed at a rate of 7.7% per year in
patients with hypertension.11 In a small cohort of Spanish
patients attending a hypertension clinic,12 moderate renal
insufficiency developed in 14% of patients over 13 years of
follow-up. In the last decade, the high frequency of renal
impairment as an epiphenomenon of cardiovascular damage
and/or cardiac dysfunction has been fully recognized. In US
Medicare patients admitted to the hospital with myocardial
infarction or heart failure, the prevalence of moderate renal
failure (creatinine clearance o60 ml/min/1.73 m2) was very
high, 60 and 52%, respectively, and these patients had a high
risk of renal disease progression.13 Similar observations also
were made in a well-organized heart failure clinic in Canada14
and in a recent analysis of the Digitalis Intervention Group
trial,15 a study that investigated the efficacy of digoxin among
stable outpatients with moderate-to-severe heart failure.
CARDIOVASCULAR RISK IN PATIENTS WITH RENAL
INSUFFICIENCY
Incident cardiovascular events both in community-based
studies (that is, in unselected populations) and in selected
populations with established cardiovascular disease are
strongly associated with the level of renal function. In the
Framingham Heart study,16 the first community study
looking into this problem, the association was evident but
restricted only to male gender. In the Atherosclerosis Risk in
Communities study, middle-aged men and women with
moderate renal insufficiency had a 38% excess risk for
incident atherosclerotic complications compared to subjects
with normal renal function.17 No excess risk was found in
subjects with renal insufficiency in the NHANES I.18
However, a well-defined risk excess emerged in an analysis
performed in NHANES II.19 A pooled analysis of four
community-based studies (including the Framingham Heart
study and the Atherosclerosis Risk in Communities study)
showed that moderate renal insufficiency carries a 19% excess
risk for cardiovascular complications.20 Renal insufficiency
signals a very high-risk situation, particularly in patients with
pre-existing cardiovascular disease. In patients with essential
hypertension, the relationship between serum creatinine
concentration and cardiovascular risk is evident even within
the boundaries of the normal range of serum creatinine. In
an Italian cohort of about 2000 hypertensive patients with
‘normal’ serum creatinine levels (that is o1.5 mg/dl in men
and o1.4 mg/dl in women) a 0.23 mg/dl higher serum
creatinine was associated with a 30% higher risk for incident
cardiovascular events.21 Data from the Syst–Eur trial showed
that in the elderly, a 10 ml lower GFR was associated with 5%
excess risk for de novo cardiovascular complications.22 In the
14,527 patients with myocardial infarction enrolled in the
Valiant study, a 10 ml lower GFR signaled a 10% increase in
risk of death or incident cardiovascular events, independently
of whether patients were treated with valsartan, captopril, or
both drugs.23 In patients with heart failure, even small
reductions in the GFR carried an important excess risk for
death both in a Canadian heart failure clinic study15 and in
the Digitalis Intervention Group trial.16
Only a tiny minority of patients (about 1%) with mild-to-
moderate renal insufficiency developed ESRD over a 5-year
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follow-up in a retrospective cohort study by the Kaiser
Permanente Center.24 However, as many as 19 and 24% of
patients with mild and moderate renal insufficiency respec-
tively died, mostly because of atherosclerotic complications,
during the same 5 years. Thus, the true risk of renal
insufficiency is cardiovascular rather renal. Cardiovascular
risk in patients who reach the end-stage phase of renal disease
is staggering, being five times higher than normal in 85–95-
year-old ESRD patients, and 65 and 500 times higher than
normal in those 45–54 years old and 25–35 years old,
respectively.25
THE CRUCIAL CARDIORENAL CONNECTION
There is a blossoming of studies describing new cardiovas-
cular risk factors. New factors are being added almost daily to
an already long catalogue including hundreds of such factors.
As much as the 75% of excess risk for coronary heart disease
in the general population could be explained by classical,
Framingham risk factors.26 The dominance of traditional risk
factors in ischemic heart disease recently has been reaffirmed
by the Interheart study,27 a case–control examination of acute
myocardial infarction in 52 countries, which included 15,152
patients and 14,820 controls, that analyzed the relation of
smoking, hypertension, diabetes, waist/hip ratio, dietary
patterns, physical activity, consumption of alcohol, blood
apolipoproteins, and psychosocial factors to myocardial
infarction. The risk attributable to dyslipidemia (raised
apolipoproteins B/apolipoproteins A1) was the highest
among the factors considered in this analysis (49.2%).
Smoking (35.7%), hypertension (17.9%), diabetes (9.9%),
abdominal obesity (20.1%), psychosocial factors (32.5%),
lack of consumption of fruits and vegetables (13.7%), lack of
regular alcohol consumption (6.7%), and of regular physical
activity (12.2%) all were significantly related to acute
myocardial infarction. These associations were noted in
men and women, old and young, and in all regions of the
world. Remarkably, the collective contribution of these nine
risk factors accounted for 90 and 94% of the population’s
attributable risk in men and women, respectively. This study
suggests that approaches to prevention of cardiovascular
disease can be based on similar principles worldwide and
have the potential to prevent most premature cases of myo-
cardial infarction. Although not considered in the Interheart
study, loss of renal function is an important element in
the natural history of cardiovascular diseases, and it brings
into the scene the importance of novel cardiovascular risk
factors.
As I mentioned, cardiovascular risk increases as renal
function deteriorates. It can be estimated that the (fully
adjusted) risk associated with moderate renal insufficiency is
about 40% higher than normal.24 The risk increases linearly
as renal function deteriorates until the GFR o15 ml/min.
Thereafter, the relationship must be exponential because in
ESRD patients, the cardiovascular death rate is 5–500 times
higher than normal.25 Thus, chronic renal insufficiency is a
strong ‘risk amplifier’. A possible explanation for why renal
function is so closely associated with cardiovascular risk is
that it simply constitutes a biologic marker of the severity
of undetected and/or detected cardiovascular disease, or a
measure of residual confounding from Framingham risk
factors; that is, renal dysfunction might be the expression of a
longer exposure to hypertension and/or to dyslipidemia.
However, risk modeling studies suggest that it is unlikely that
the excess risk for patients with chronic renal insufficiency
can be explained only on the basis of traditional risk
factors.28,29
In recent years, substantial progress has been made in
identifying risk factors specific to patients with uremia. The
huge risk excess associated with renal insufficiency might
depend in part on the fact that renal dysfunction produces a
positive sodium balance. The resulting extracellular volume
expansion imposes a chronic volume and pressure burden on
the left ventricle, ultimately producing left-ventricular remodel-
ing and heart failure. Anemia, high calcium–phosphate product,
inflammation, hyperhomocysteinemia, and impaired nitric
oxide (NO) synthesis, due to accumulation of NO synthase
inhibitors, all might contribute to the increase in cardiovascular
risk in patients with ESRD.29 Most of these factors affect
generation of reactive oxygen species. High oxidative stress
mediates the adverse effects of a multitude of risk factors on the
ardiovascular system.30 Yet no prospective study in CKD has
provided convincing proof of such a link. Genetic factors, such
as gene polymorphisms that regulate homocysteine levels, the
renin–angiotensin system, and the endogenous antioxidant
system itself, also are important. Furthermore, an absolute or
relative deficiency in endogenous vasoprotectors such as
adiponectin31 might contribute to vascular damage.
Classical risk factors dominate the scene in the early stages
of chronic renal insufficiency because most individuals who
develop renal dysfunction have a long history of hyperten-
sion, diabetes, dyslipidemia, smoking, or a combination of
these. Within the kidney, afferent vasoconstriction plays a key
role in protecting the glomerular tuft from systemic pressure.
In hypertensive patients, the afferent arteriole shows
muscular hypertrophy and hyaline transformation, which
lead to glomerular ischemia and tubulo-interstitial changes.32
Males and smokers have an increased risk of these changes.
Moreover, dyslipidemia is harmful both to the vascular
system and to the kidney, and Diamond33 has suggested that
focal glomerulosclerosis is the glomerular equivalent of
atherosclerosis. Diabetic nephropathy causes specific glomer-
ular alterations and, nephrosclerosis is common in patients
with diabetes mellitus.34
Traditional risk factors are considered dominant for
triggering initial renal damage and cardiovascular events in
the general population, but non-traditional risk factors –
anemia and other emerging risk factors discussed below –
become increasingly important as renal function worsens.
Anemia
The first signs of anemia become evident when GFR falls
below 50 ml/min; on average, hemoglobin concentration is
28 Kidney International (2006) 70, 26–33
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2.5 g/dl lower in patients with GFR 50–25 ml/min than in
those with GFR 450 ml/min, and a 0.5/dl decrease in
hemoglobin concentration is associated with a 1.3-fold
increased incidence of LVH.35 However, it is unknown
whether early treatment of anemia in patients with renal
chronic renal insufficiency prevents LVH in these patients.
Initial studies in animal models suggested that a higher
hematocrit may accelerate renal function loss in the rat.
However, observations in humans indicate that better control
of anemia is unlikely to have detrimental effects on the
progression of renal insufficiency.36 Treatment of anemia
might improve symptoms of heart failure37 but there is no
solid evidence that correction of anemia in heart failure
affects the high death rate of this condition. Furthermore, it
remains still to be proven that anemia increases life
expectancy in patients with ESRD.38
Hyperphosphatemia and hyperparathyroidism
These constitute the second cardiovascular risk factor
commonly seen in patients with chronic renal insufficiency.
The severity of secondary hyperparathyroidism in chronic
renal insufficiency is GFR dependent and associated with
cardiovascular disease. Indeed hyperparathyroidism is asso-
ciated with a history of myocardial infarction and heart
failure.39 A strong association has been described between
hyperphosphatemia and incident cardiovascular events in
ESRD patients. Although further studies based on hard end
points are still required, the link between hyperparathyroi-
dism–hyperphosphatemia and cardiovascular complications
probably is a causal one because vascular calcifications do not
progress in patients with better control of hyperphosphate-
mia and hypercalcemia, while vascular calcifications worsen
in patients with poor control of the plasma concentration of
these substances.40 The pathogenesis of cardiovascular
calcifications is presently one of the most investigated in
nephrology41 and evidence is emerging that optimizing
treatment of calcium and phosphate alterations may decrease
cardiovascular risk in patients with CKD.42
Hyperhomocysteinemia
Hyperhomocysteinemia might trigger renal damage. In the
Horn study, high plasma homocysteine was associated with
microalbuminuria independently of other risk factors.43 In a
community-based study in individuals without renal disease
at baseline, the risk of moderate-to-severe renal insufficiency
(GFRo60 ml/min) was three times higher in individuals
with serum homocysteine in the tertile than in those in the
lowest tertile.44 Plasma homocysteine concentration increases
as renal function worsens,45 typically ranging between 20 and
50 mmol/l in patients who reach ESRD. The increase in
plasma concentration associated with moderate renal in-
sufficiency is about 5 mmol/l. Such an increase may be
important because in a meta-analysis by Wald et al.,46 a
5mmol/l higher plasma homocysteine was associated with a
42% higher risk of coronary heart disease death. We reviewed
seven prospective observational studies in ESRD, including
more than 1000 hemodialysis and 176 continuous ambula-
tory peritoneal patients. We looked at the relationship
between homocysteine and mortality and/or cardiovascular
events, and we noted positive and negative associations.47
Disparate results in these studies contrast with experimental
findings indicating that this sulfur amino acid is vasculotoxic.
As homocysteine circulates bound to albumin, negative
associations, rather than negating its vasculotoxicity, might
reflect the deleterious effects of malnutrition. In a study
in hemodialysis patients that excluded patients with heart
failure at baseline (heart failure is a frequent (30%) cause of
severe malnutrition in the dialysis population), homocysteine
was unrelated to all-cause mortality but strongly associated
with incident atherothrombotic events.48 The problem is
similar to that posed by excessive interdialysis weight gain,
which is both an expression of excessive cyclic volume
overload (and therefore a strong cardiovascular risk factor)
and an indicator of adequate nutrition. In one study,
interdialysis weight gain,49 was inversely rather than directly
related to mortality in these patients. Ongoing intervention
studies, like the FAVORIT trial (http://www.cscc.unc.edu/
favorit/favdescrip.htm), will establish whether homocysteine
lowering decreases cardiovascular complications in renal
transplant patients and will provide also information useful
to the treatment of patients with CKDs.
C-reactive protein and other atherogenic mechanisms
triggered by inflammation
The link between inflammation (as measured by C-reactive
protein (CRP)) and renal function is established at an early
stage in chronic renal disease. This association was well
demonstrated in the PREVEND study.50 In this study,
patients were stratified into four quartiles according to
serum CRP. When these quartiles were related to creatinine
clearance, even though creatinine clearance was on average in
the normal range in all quartiles, it was significantly less in
patients with high CRP (fourth quartile) than in those with
low CRP (first quartile) (Figure 1). Although a recent meta-
analysis suggests that the role of serum CRP as a risk factor in
the general population might have been overemphasized,51
considerations in the general populations do not apply to
chronic renal insufficiency, a high-risk population where
CRP most often signals a severe degree of target organ
damage (see below). There is still a lack of intervention
studies that lowering CRP may retard renal disease progres-
3rd2nd1st 4th
CRP quartiles
Creatinine Cl
(ml/min/1.73 m2)
100
95
90
PREVEND study, Kidney Int 2003; 63: 654.
Figure 1 | Relationship between serum CRP and creatinine
clearance in the PREVEND study.
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sion and reduce cardiovascular complications in patients
with CKD. In a secondary analysis of three randomized
controlled trials Tonelli found that pravastatin slightly retards
(8%) renal function loss52 and produces an important
decrease in the incidence rate of cardiovascular events
(33%)53 in patients with or at risk for coronary heart
disease. When renal function approaches 0, serum CRP
attains very high levels.54–56 In ESRD, CRP is strongly
associated with increased risk of death and cardiovascular
events.57,58 However, atorvastatin failed to reduce cardiovas-
cular events in diabetic uremics on chronic dialysis in the
German Diabetes and Dialysis study (4D).59 Inflammation, a
fundamental promoter of atherosclerosis, interacts with
many pathophysiologic pathways that lead to vascular
damage. In vitro, inflammatory cells (monocyte-macrophage)
potentiate alkaline phosphatase activity of osteoclast-like cells
in the vascular system;60 this suggests that inflammation
favors vascular calcification. In line with this hypothesis,
Wang et al.61 showed that cardiac valve calcifications are
much more frequent in ESRD patients with high CRP levels
than in those with relatively lower levels. Inflammation also
interacts with several pro-atherogenic mechanisms. One
major inflammatory molecule, interleukin-6, stimulates
fibrinogen synthesis via a specific interleukin-6-sensitive
sequence in the fibrinogen gene; this pathway leads to
thrombosis. Fibrinogen is at center stage in mediating the
cardiovascular damage seen in ESRD patients. Of note, recent
mechanistic studies by Kaysen and Don62 suggest that the
synthesis rate of this acute-phase reactant is strongly
associated with that of albumin, which in turn is linked to
plasma volume. In accord with this hypothesis, plasma
fibrinogen was directly related to left-atrial volume in an
analysis of patients in the Cardiovascular Risk Extended
Evaluation (CREED) database.47 This association cannot be
attributed to the confounding effect of diastolic dysfunction
on atrial volume because diastolic rate was almost unmodi-
fied after statistical adjustment for the E/A ratio. The
association between plasma fibrinogen, concentric LVH63
and all-cause death and incident cardiovascular events is well
established in hemodialysis patients.64 Thus multiple me-
chanisms, both inflammation dependent and -independent,
cooperate in determining the high atherothrombotic risk of
ESRD. The 4D study clearly indicates that intervening with a
statin in the terminal, ESRD phase is unlikely to modify the
dim cardiovascular prospects of patients with chronic renal
diseases.
Sympathetic overactivity
Sympathetic activity measured by direct recording of
sympathetic bursts in the peroneal nerve, the most reliable
technique for estimating sympathetic nerve activity, is
increased and strongly involved in the pathogenesis of
hypertension in patients with mild-to-moderate renal
insufficiency.65 While hypertension is seen as an important
cause for cardiovascular complications in patients with
chronic renal insufficiency, it is not widely realized that
increased sympathetic activity per se might be implicated in
hypertension and renal disease progression, and an indepen-
dently trigger cardiovascular events as well. While no
evidence yet links sympathetic activity with cardiovascular
complications in the pre-dialysis phase, it was shown that
plasma norepinephrine is an independent predictor of new
cardiovascular events in ESRD patients.66 The mechanisms
responsible for sympathetic overactivity in renal disease are
largely unknown. Sleep apnea, a frequent complication of
chronic renal insufficiency, is one important mechanism
given that sympathetic activity is increased in patients with
primary sleep apnea.67 Thorough elucidation of the relation-
ship between sleep apnea and raised sympathetic activity is
important because it was shown that nocturnal hypoxemia
triggers cardiovascular events in ESRD.68 Other mediators of
cardiovascular and renal damage induced by sympathetic
over-activity remain to be elucidated. I should point
out, however, that norepinephrine induces hypertrophy of
myocardial cells in vitro and this finding is consistent with
our clinical observation that the plasma concentration of this
catecholamine is strongly and independently associated with
concentric LVH in ESRD patients.69 The adverse effects of
high sympathetic activity are intimately associated with
altered regulation of the NO system. Reduced NO synthesis
might lead to sympathetic overactivity and, in turn, increased
sympathetic activity might lead to reduced NO synthesis and
endothelial dysfunction.
ENDOTHELIAL DYSFUNCTION AND REDUCED NO SYNTHESIS
The role of endothelium in renal dysfunction in humans is
highlighted by our observation that impaired vasodilatory
response to acetylcholine (an established hemodynamic
marker of endothelial function) is strongly associated with
impaired renal function in patients with essential hyperten-
sion.70 Endothelial dysfunction, a pro-atherogenic alteration,
is pervasive in chronic renal disease. Among the various
factors invoked to explain this alteration, accumulation of the
endogenous inhibitor of NO synthase, asymmetric dimethy-
larginine (ADMA), appears to be of primary importance.
This substance accumulates from the very outset of renal
disease, when the GFR is normal.71 ADMA infused
intravenously into healthy subjects to bring the plasma
concentration of this substance into the pathophysiologic
range causes a distinct increase in arterial pressure as well as
sodium retention;72 this finding is consistent with the
observation that salt-sensitive individuals exhibit higher
plasma ADMA levels than do salt-resistant ones.73 High
ADMA levels can aggravate the inherently limited ability of
patients with chronic renal insufficiency to excrete sodium.
An intact NO system is important for preventing renal
disease progression in experimental models,74 and this issue
now deserves careful investigation in humans. ADMA
accumulation and the ensuing NO inhibition might accel-
erate renal disease progression. In a recent study, in a cohort
of patients with an average age of 71 years ADMA was
inversely related to the GFR and predicted progression of
30 Kidney International (2006) 70, 26–33
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renal disease to dialysis.75 The predictive power of ADMA for
renal disease progression is not limited to old patients
because almost identical findings have been reported in a
middle-aged cohort of CKD patients.76 In patients with
chronic nephropathies ADMA increases linearly with renal
function loss75,76 to reach levels 2–3 times higher than normal
in patients with ESRD. Increased ADMA levels are associated
with high cardiovascular risk in the general population. In a
community level study in Finland, the incidence rate of
cardiovascular events in men in the 4th ADMA quartile was
3.9 higher than in those in the other quartiles.77 The risk
associated with high ADMA levels does not flatten out at the
pathophysiologic levels. Indeed patients with ESRD, those
with the highest ADMA levels, the risk of incident
cardiovascular events increased across the whole range of
ADMA values78 (Figure 2).
As I alluded to before, NO influences sympathetic
function and vice versa. NO inhibition increases sympathetic
activity.79 In turn, sympathetic activation in vivo in humans
reduces NO-mediated forearm vasodilation.80 In ESRD
patients these two risk factors may be in the same pathogenic
pathway leading to cardiovascular complications. In fact,
plasma norepinephrine, a strong and independent predictor
of adverse cardiovascular outcomes,66 loses substantial
predictive power in models including plasma ADMA; this
suggests that ADMA is a mediator of the atherogenic effects
of increased sympathetic activity.81
Thus, several novel risk factors other than the traditional
Framingham risk factors are present in mild renal insuffi-
ciency. Moreover, their adverse impact increases as renal
insufficiency worsens.
Preventive strategies
Controlling the epidemic of chronic renal insufficiency
should be seen as a part of a large-scale preventive strategy
targeting the rising tide of the ‘metabolic syndrome’ in the
general population. Indeed, risk factors for the metabolic
syndrome are strongly associated with chronic renal
insufficiency at the population level.82 A healthy lifestyle
(in which patients stop smoking; eat foods low in saturated
fats, cholesterol, and salt; and participate in regular exercise)
might prevent or retard hypertension, hyperlipidemia, and
diabetes, thereby preventing or slowing the cardiovascular
and renal sequelae of this syndrome. Comprehensive screen-
ing programs aimed at detecting individuals at risk for the
metabolic syndrome should include GFR and albuminuria
measurements to detect disease in the early, asymptomatic
phase, and stop it from progressing. In patients with
established renal insufficiency, interventions should be taken
to prevent further deterioration and to reduce cardiovascular
complications.
Hypertension control in patients with renal insufficiency
remains unsatisfactory. Indeed, in the Target Blood Pressure
Levels in Chronic Kidney Disease survey, as 88% of patients
had blood pressure values exceeding target levels recom-
mended by national and international guidelines.83 In this
study, poor compliance with a low-sodium diet and
suboptimal prescription of diuretics emerged as major
problems in achieving treatment goals. Research aimed at
modifying novel risk factors for cardiovascular and renal
disease appears of paramount importance in patients with
established renal insufficiency. Early treatment of anemia can
reduce LVH in patients with progressive renal diseases. The
Cardiovascular risk Reduction by Early Anemia Treatment
with Epoetin Beta (CREATE) study will soon provide an
answer to this problem.84 As discussed, the (4D) suggests that
interventions started in ESRD might not be sufficient to
prevent cardiovascular events in type 2 diabetics with ESRD.
The Study of Heart and Renal Protection (HARP-I)85 and the
Esplanade study will give important information on the role
of inflammation in the high rate of cardiovascular events and
renal disease progression in patients treated at earlier stages.
Likewise, the previously mentioned Folic Acid for Vascular
Outcome Reduction in Transplantation (FAVORIT) study
assessing the effect of pharmacologic doses of folic acid and
vitamins B6 and B12 on cardiovascular risk in transplant
patients will provide information that can be extended to
patients with CKD.
In addition to research into new and established risk
factors, it is important that nephrologists make the best use
of knowledge already available to optimize the follow-up of
patients with mild renal insufficiency. Guidelines are at
central stage in modern medicine. Doctors, patients, health
providers, and politicians all perceive the potential impact of
clinical practice guidelines implementation on public health.
However, implementation and evaluation of guidelines have
received only scant attention as compared with development
and promulgation. Public health would be much improved if
we were able to better apply what we have learned from the
blossoming of clinical research studies of the last 30 years or
so.86 We need to identify barriers to the application in
everyday clinical practice of coherent, integrated treatments
for retarding renal disease progression and for preventing
cardiovascular risk. Every effort should be made to streamline
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cardiovascular events 1.0
0.9
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Figure 2 | Relationship between ADMA and cardiovascular events
in the CREED study.
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the collaboration between hospital departments and physi-
cians to improve follow-up of high-risk patients, particularly
in identifying ‘problematic’ and/or treatment-resistant pa-
tients. New forms of collaboration between clinical and
academic centers and physicians ought to be planned and
tested, such as, outpatient clinics incorporating cardiorenal
clinics for high-risk patients, or well-focused internet services
and consultations.
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